

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

MYLAN PHARMACEUTICALS INC., and
DR. REDDY'S LABORATORIES, INC.

Petitioners

v.

HORIZON PHARMA USA, INC. and NUVO PHARMACEUTICALS
(IRELAND) DESIGNATED ACTIVITY COMPANY,

Patent Owners.

Case No. IPR2017-01995¹
U.S. Patent No. 9,220,698

**JOINT REQUEST THAT SETTLEMENT AGREEMENT BE TREATED AS
BUSINESS CONFIDENTIAL INFORMATION AND KEPT SEPARATE
PURSUANT TO 35 U.S.C. § 317(b) AND 37 C.F.R. § 42.74(c)**

¹ Petitioner Dr. Reddy's Laboratories, Inc., from IPR2018-00894, has been joined as
a Petitioner to this proceeding.

Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c), Petitioner Mylan Pharmaceuticals Inc. (“Mylan”) and Patent Owners Horizon Pharma USA, Inc. and Nuvo Pharmaceuticals (Ireland) Designated Activity Co. (“Patent Owners”) jointly request that the settlement agreement filed concurrently herewith (Ex. 1059) and referenced in the concurrently-filed Joint Motion to Terminate Petitioner Mylan Pharmaceuticals Inc. be treated as business confidential information and kept separate from the files of the involved patent and only made available to Federal Government agencies upon written request or to any other person upon written request and a showing of good cause.

Dated: July 29, 2019

/Brandon M. White/

Brandon M. White

Reg. No. 52,354

PERKINS COIE LLP

700 13th Street, NW, Suite 600

Washington, D.C. 20005

Telephone: (202) 654-6206

Facsimile: (202) 654-6211

Email: bmwhite@perkinscoie.com

Attorney for Mylan Pharmaceuticals Inc.

CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing Joint Request That Settlement Agreement Be Treated as Business Confidential Information and Kept Separate Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c) and Exhibit 1059 was served electronically via email as follows:

Thomas A. Blinka
Jonathan G. Graves
Ellen Scordino
Cooley LLP
zIPR2017-01995@cooley.com

Margaret J. Sampson
Stephen M. Hash
Jeffrey S. Gritton
Baker Botts LLP
nuvo-vimovoBB@bakerbotts.com

The undersigned hereby certifies that the foregoing Joint Request That Settlement Agreement Be Treated as Business Confidential Information and Kept Separate Pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c) (without Exhibit 1059) was served electronically via email as follows:

Alan H. Pollack
Stuart D. Sender
Louis H. Weinstein
Windels Marx Lane & Mittendorf, LLP
apollack@windelsmarx.com
ssender@windelsmarx.com
lweinstein@windelsmarx.com

Date: July 29, 2019

/Brandon M. White/
Brandon M. White
Reg. No. 52,354
Attorney for Mylan Pharmaceuticals Inc.